Company Overview - Zhejiang Hai Zheng Pharmaceutical Co., Ltd. has received approval for its new veterinary drug, non-rocoxib chewable tablets, which are designed to alleviate pain and inflammation in dogs [1] - The approval of this drug marks a significant milestone in the company's strategic positioning within the veterinary medicine sector, enhancing its market competitiveness [1] Business Development - Hai Zheng Pharmaceutical has been focusing on the pet medicine sector, transitioning from its original emphasis on economic animals since 1992, and has made notable progress in recent years [2] - As of the end of 2024, the company operates two production bases with 25 production lines and has over 40 products with 71 approved registration numbers [2] - The company's e-commerce performance has surpassed 100 million yuan in 2024, with a cumulative growth of 11 times over five years, indicating a strong expansion in its pet medicine business [2] Financial Performance - In 2024, the revenue from anti-parasitic and veterinary products reached 713 million yuan, reflecting a year-on-year decline of 14.07%, although the gross profit margin increased by 1.55 percentage points due to improved cost control [2] - Despite not yet achieving profitability, the subsidiary Hai Zheng Animal Health reported a revenue increase of 3.21% to 410 million yuan [2][3] Industry Trends - The pet medical industry in China is experiencing rapid growth, with the market size reaching 94 billion yuan in 2024, a year-on-year increase of 14.49% [4] - The approval of 52 new pet drugs by the Ministry of Agriculture and Rural Affairs in 2024, with 31 being domestically produced, indicates a significant enhancement in domestic drug development capabilities [4] - The integration of AI technology in the pet medical field, exemplified by the launch of the Vet1 AI model, represents a breakthrough in the industry [4] Future Outlook - The pet medical market is expected to continue expanding as pet owners increasingly prioritize their pets' health, driven by technological advancements and new medical models [5] - Companies are encouraged to leverage opportunities through innovation, service upgrades, and strategic partnerships to enhance competitiveness and promote sustainable industry growth [6]

原料药是制药产业链的起点，"原料药好，药才好"，好品质的核心一定是对源头的把控。海正药业多年来一直坚守原料药的根基。在生产方面，海正药 业国际化标准的生产基地重点分布在台州、富阳、南通，目前产线布局完整，具有发酵17000立方、合成2300立方的生产能力。 "重回国内第一梯队"是海正药业（600267）十五五战略规划的目标。构建以人用药为主、以动物药和医美大健康为两翼的一"主"两"翼"多元发展格局， 是未来五年海正药业为发展制定的明确路径。 来到位于杭州富阳的产业园区，一座被绿意环抱的产业群落就是海正药业在2002年布局的原料药、医药制剂生产基地。如今，当初的药用植物种植基地 已经发展为占地1500余亩的生物医药产业园，业务版图涵盖高端生物技术药物、注射和口服制剂、出口原料药、兽用原料药四大领域。 守牢原料药好品质 海正药业是中国原料药出海最早的企业之一，早在1992年便将产品打入美国市场，至今原料药产品出口至70多个国家和地区，广泛覆盖医药及医疗领 域，拥有海外客户400余家（含全球十大药企）。 在近70年的风雨洗礼中，这家老牌药企已经逐渐发展成为集研产销全价值链、原料药与制剂垂直一体化的全球化制药企业。目 ...

记者了解到，目前海正药业富阳基地已成功承接硕腾、柯迪华等国际巨头的CMO订单，并持续推进依 维莫司等新产品注册，未来有望成为国际医药产业链的重要一环。 在医药制剂业务方面，海正药业率先在国内实现注射剂出口美国市场，保持国际领先GMP水平，将国 际标准与中国制药实际需求深度结合。海正药业医药制剂业务主要由全资子公司瀚晖制药负责，瀚晖制 药独创"三严四化"质量管理模式，引进原研药技术并实现本地化生产，目前已成功完成玫满、多达一、 特治星、美卓乐、甲强龙五款境外原研产品的技术转移，填补国内原研产品地产化转移技术空白。如 今，瀚晖工厂是国家短缺药和小品种生产基地，解决了多个短缺药品种的临床供应保障问题。 动物药板块是海正药业重点扶持打造的具有高潜力的业务板块，海正药业主要通过旗下海正动保布局动 物健康领域。据悉，海正动保依托云南生物疫苗基地与富阳化药基地，搭建起覆盖猪、反刍、宠物三大 类产品群的产品矩阵，海正动保拥有15个国家二类新兽药证书、20个在研产品、60余个批准文号、10余 个单品销售超千万的产品，且多款产品创下行业纪录，如海乐妙成为首个销售额破亿的国产驱虫药、海 乐旺成功登陆越南市场、推出品牌首款国产猫三联 ...

经营稳健发展下，5月12日晚，海正药业发布《关于第四次以集中竞价交易方式回购股份方案暨回购报 告书》，拟以自有资金5000万至1亿元回购公司股份，回购价格不超过13元/股。这是公司第四次实施股 份回购计划，充分彰显了管理层对公司长期发展的坚定信心。 加速全球化布局 盈利能力持续提升，海正药业（600267）(600267.SH)实施回购提振市场信心。 日前，海正药业发布《关于第四次以集中竞价交易方式回购股份方案暨回购报告书》，公司拟以自有资 金5000万至1亿元回购公司股份，回购价格不超过13元/股。这是公司第四次实施股份回购计划，充分彰 显了管理层对公司长期发展的坚定信心。 长江商报记者注意到，近年来，公司通过持续优化业务结构、加码创新研发、推进国际化战略，已经逐 步实现了从传统制药企业向创新驱动型企业的转型。特别是在合成生物学、高端制剂等新兴领域的布 局，正在为公司培育新的增长点。 2025年一季报显示，报告期，公司营业收入26.32亿元，同比下降3.48%；归母净利润1.94亿元，同比下 降21.85%。不过，由于制剂产品销售增长带来销售利润增加以及管理费用和财务费用下降，扣非净利 润同比增长36.94 ...